This site uses optional cookies which are currently not set, but will be if you visit another page. Find out more about the cookies we use



2017 BioInfect Conference

Location: Alderley Park Conference Centre, Cheshire

A major 1-day conference looking at the critical issues relating to the development of new anti-infectives and the endemic problem of resistance.

Antimicrobial resistance occurs when microorganisms such as bacteria, viruses, fungi and parasites change in ways that render the medications used to cure the infections they cause ineffective. When the microorganisms become resistant to most antimicrobials they are often referred to as “superbugs”. This is a major concern because a resistant infection may kill, can spread to others, and imposes huge costs to individuals and society.

Antimicrobial resistance threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi. It is an increasingly serious threat to global public health that requires action across all government sectors and society.

Conference Programme





Coffee & Registration


Welcome to the Conference

Geoff Davison, Chief Executive Officer, Bionow


Keynote Address

Tyler Merkeley, CARB-X Program Manager, BARDA


State of the AMR Nation

Session Chair: Jo Pisani, Pharmaceutical and Life Science Consulting Leader, PwC
Tyler Merkeley, CARB-X Program Manager, BARDA
Pete Jackson, Executive Director, AMR Centre
John Fitzgerald, Secretary General, RUMA
Jonathan O'Halloran, Chief Scientific Officer, QuantuMDx
Richard Seabrook, Senior Advisor - AMR Lead, Medicines Discovery Catapult


Coffee, Networking & Exhibiton


Making Progress - Active Programmes to Advance the Antibiotic Pipeline: Part 1

Peter Warn, Senior Vice President Anti-Infective Discovery, Evotec / Forge Therapeutics
Jean de Gunzberg, Chief Scientific Officer, Da Volterra
Giancarlo Biagini, Professor, Liverpool School of Tropical Medicine


Antibacterial Drug R&D Strategies: Medical Need and Public Support

Ursula Theuretzbacher, Founder & Principal, Centre for Anti-Infective Agents 


Lunch, Networking & Exhibition



Making Progress - Active programmes to Advance the Antibiotic Pipeline: Part 2

Glenn Dale, Head of Early Development Antimicrobials, Polyphor
Emma Leire, Microbiology Team Lead, Centauri Therapeutics
Paul Ko Ferrigno, CEO, MetaLinear
Irina Barbolina, Senior Biologist & Laboratory Manager, LIG Biowise


Funding and Building Partnerships

Session Chair: Pete Jackson, AMR Centre
Gabriela Juarez-Martinez, UK China Partnership
Claire Thompson, Royal Pharmaceutical Society
Shampa Das, Molecular and Clinical Pharmacology, University of Liverpool
Colin Garner, Chief Executive, Antibiotics Research UK


Closing Remarks

Delegate Fees*
Premium Member: £150.00 + VAT
Member: £175.00 + VAT
Non-Member: £275.00 + VAT

To discuss the sponsorship and exhibition opportunities at the conference, please contact Helen Williams at or on 07714 168020.

> Register here